Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
Company Details
- Employees
- 50
- Address
- Cambridge, Massachusetts 02142, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.avalynpharma.com
- Keywords
- jobs.
- HQ
- Cambridge, Massachusetts
Avalyn Pharma Questions
Avalyn Pharma's website is http://www.avalynpharma.com
Avalyn Pharma's LinkedIn profile is https://www.linkedin.com/company/avalyn-pharma-inc
Avalyn Pharma has
50 employees.
View email and phone details for 50
employees at Avalyn Pharma.
Avalyn Pharma's industry is
Biotechnology Research
Avalyn Pharma's top competitors are
Airna,
Nuvalent, Inc.,
Quiver Bioscience,
Seaport Therapeutics,
Kalvista Pharmaceuticals, Inc.,
Oddity Labs,
Delphia Therapeutics,
Pledge Therapeutics,
Myrobalan Therapeutics,
Nona Biosciences.
Avalyn Pharma's categories are Biotechnology Research
